FDA to reconsider Braeburn’s opioid addiction drug after court rulingA US district court has ruled that the FDA must reconsider its decision to reject a long-lasting opioid Share XFDA to reconsider Braeburn’s opioid addiction drug after court rulinghttps://pharmaphorum.com/news/fda-to-reconsider-braeburns-opioid-addiction-drug-after-court-ruling/
Indivior stung by fraud charges over US marketingShares in UK drugmaker Indivior have gone into freefall after it was charged by the US Department of Share XIndivior stung by fraud charges over US marketinghttps://pharmaphorum.com/news/indivior-stung-by-fraud-charges-over-us-marketing/
Ensuring delivery of healthcare professional educationPharma companies always need to know they can get the right information to the right people at the Share XEnsuring delivery of healthcare professional educationhttps://pharmaphorum.com/debates-insight-sales-marketing/ensuring-delivery-of-healthcare-professional-education/
Indivior hit hard as generic Suboxone defence crumblesIndivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the Share XIndivior hit hard as generic Suboxone defence crumbleshttps://pharmaphorum.com/news/indivior-hit-hard-as-generic-suboxone-defence-crumbles/
Indivior’s once-monthly schizophrenia injection gets US green lightRegulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia. Perseris (risperidone) won Share XIndivior’s once-monthly schizophrenia injection gets US green lighthttps://pharmaphorum.com/news/indivior-schizophrenia-perseris-fda/
